Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Invesco Solar ETF (TAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Invesco Solar ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Invesco Solar ETF trades at $42.3 (market cap $881.52M). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 8.5× Invesco Solar ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Invesco Solar ETF for 35 Days on average.
| SYRE | TAN | |
|---|---|---|
Market Cap | $7.52B | $881.52M |
Volume | 1,441,031 | 3,915,267 |
Sector | Health | Sector/Thematic |
52-Week High | $108.92 | $73.95 |
52-Week Low | $22.18 | $42.64 |
Typical Hold Time | 0 Days | 35 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
TAN trades at $44.38, up 2.07% today but facing bearish technical signals with sell signals outweighing buys 11-8. The solar ETF shows mixed sentiment amid sector volatility, with recent news highlighting both policy tailwinds from U.S. tariffs and headwinds from high borrowing costs impacting project financing.
Outlook remains cautious due to sector-specific risks including interest rate sensitivity and market saturation concerns. While geopolitical shifts favor renewable energy adoption, TAN's high expense ratio and historical underperformance versus broad market indices present challenges for investors seeking stable returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
